Clinical Trial Update: Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating bendamustine plus rituximab as initial therapy for previously untreated extranodal MALT lymphoma; the study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Drugs mentioned

• Rituximab (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: MALT LYMPHOMA | Phase 2 | Status: COMPLETED